Top 5 Medical Device VC (Venture Capital) Funds in Iceland in April 2025
A list of 5 VC (Venture Capital) funds that invest in Medical device startups based in Iceland. We rank investors based on the number of investments they made in Medical device companies from Iceland. We update this investor list every month.Top 5 Medical Device VC (Venture Capital) Funds in Iceland in April 2025
Investor | Medical Device Iceland investments |
---|---|
Novator | 3 |
New Business Venture Fund | 2 |
Silicon Valley Bank | 2 |
Frumtak Ventures | 2 |
Wellington Partners | 1 |
Novator is an alternative investment firm founded and led by the international investor and entrepreneur Thor Bjorgolfsson.Novator's investment portfolio is focused around following sectors: Telecommunications, Pharmaceuticals, IT and Renewable Energy. In addition, Novator operates a Private Equity Fund and a Credit Opportunities Fund.Novator focuses on developing strong management teams in each of its portfolio companies. While granting them the autonomy to create value, Novator maintains a supervisory role, principally through representation on the Boards of its investee companies. Novator differentiates itself from many other private equity companies in concentrating on complex situations, either by virtue of their structure or their cross-border nature. To create value, Novator undertakes the restructuring or "de-risking" of investment opportunities through re-financing, combining acquired assets with existing businesses, through sale to strategic or financial buyers, or through flotation. Novator's investment portfolio is focused around four main sectors:Telecommunications, Pharmaceuticals, IT and Renewable Energy.
Show more
Investment focus
- Software, E-Commerce, Online Games
- Funding Round, Series B, Series C
- United Kingdom, United States, Iceland
Portfolio highlights
- Nord Security — Nord Security is the leader in the field of online privacy and security. Our security tools have earned praise from respected experts and tech outlets.
- Better.com — Better Mortgage Corporation is a direct lender dedicated to providing a fast, transparent digital mortgage experience backed by superior customer support.
- Steel City Interactive — Steel City Interactive develops gaming.
The New Business Venture Fund is an evergreen investment fund that actively contributes to the development and growth of the Icelandic economy by investing in promising innovation and start-up companies.The New Business Venture Fund invests at seed and early stage in promising growth companies with great business ideas and strong management anddevelopment teams.The New Business Venture Fund is a state owned investment fund intended to strengthen and develop the Icelandic venture capital market along with promoting startups and business in Iceland thus encouraging economic growth.
Show more
Investment focus
- Software, Health Care, Medical
- Seed, Funding Round, Series A
- Iceland, United States, China
Portfolio highlights
- HorseDay — HorseDay is a mobile application to track horse activities.
- Spectaflow — Spectaflow is a SaaS solution for accommodations businesses focused on improving housekeeping and maintenance workflows
- PayAnalytics — PayAnalytics, a leading pay equity and workforce analytics solution, aids companies in closing pay gaps and fostering workplace equity. Ensure compliance with pay transparency regulations, assess wage disparities, and analyze workforce demographics conveniently.
Silicon Valley Bank is the financial partner of the innovation economy; helping individuals and investors in the innovation ecosystem achieve extraordinary outcomes.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Debt Financing, Series B, Series A
- United States, United Kingdom, Canada
Portfolio highlights
- Chimerix — Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA(dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix’s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.
- Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.
- TScan Therapeutics — Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien velit, aliquet eget commodo nec, auctor a sapien. Nam eu neque vulputate diam rhoncus faucibus. Curabitur quis varius libero.
At Frumtak Ventures, we champion founders who have demonstrated early traction and have potential to become global leaders in their space. We take a concentrated, high-conviction, and high-involvement approach to investing and dedicate ourselves to collaboratively work with our portfolio companies from the seed stage through IPO. Our initialticket size usually ranges from €1 million to €3 million.
Show more
Investment focus
- Software, Information Technology, Enterprise Software
- Seed, Funding Round, Series A
- Iceland, United States, United Kingdom
Portfolio highlights
- PLAIO — The only AI-assisted decision-making platform developed for pharmaceutical manufacturing
- Moombix — Join us for the launch of our advanced learning platform for online music lessons
- Treble — We develop next generation sound simulation and spatial audio technology for digital twins and virtual worlds.
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series A, Series B, Funding Round
- Germany, United States, United Kingdom
Portfolio highlights
- Nosto — Use Powerful Personalization Made Easy on e-Commerce Platforms. Nosto generates a 10-30% Average Increase in Revenue.
- Minervax — MinervaX is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein : click to read more
- Seamless Therapeutics — Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Seamless technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes.
Investors by industry
Proptech
Impact
Hardware
Gaming
Google
Consumer
Energy
Climate
Marketplace
FinTech
Health Care
Community
Artificial intelligence
Biotech
EdTech
Sustainability
Venture Capital
Organic Food
Real Estate
Web3
Big Data
Education
Finance
Video Games
Payments
Publishing
Food and Beverage
Financial Services
Retail
Clean Energy
B2B
Photography
Infrastructure
Beauty
Social Media
Android
Art
Digital Media
Platforms
Social Network
Mobile Advertising
Recruiting
Biotechnology
Hospitality
Cannabis
Franchise
Fitness
Travel
Construction
Automotive
Wine And Spirits
Medical Device
Local
Crowdfunding
eSports
Social
CleanTech
Legal
Mobile Apps
Transportation
Enterprise Software
InsurTech
Enterprise
Internet
Sports
Medical
Email
Wellness
Music
LGBT
Manufacturing
Mobile
Theatre
Fashion
Oil and Gas
Film
Life Science
SaaS
Non Profit
Renewable Energy
Sporting Goods
Restaurants
Celebrity
Software
Social Impact
Cryptocurrency
Facebook
Machine Learning
Agriculture (agtech)
Media (entertainment)
Blockchain
Investors by country
Germany
United Kingdom
India
New Zealand
Canada
Ireland
Australia
United States
South Korea
China
Oceania
Japan
Sri Lanka
Singapore
Europe
Indonesia
South Africa
Vietnam
LATAM
Spain
Armenia
Brazil
Africa
Middle East
Qatar
Georgia
Asia
Ecuador
Bahrain
Faroe Islands
Belize
Egypt
Croatia
Greece
Ghana
Saudi Arabia
Hungary
Finland
Estonia
Costa Rica
Czech Republic
Ethiopia
France
Belgium
Liberia
Hong Kong
Barbados
Gibraltar
Bermuda
Kuwait
Belarus
Algeria
Chile
Denmark
Peru
Bulgaria
Tajikistan
Togo
Seychelles
Poland
Zimbabwe
Tanzania
Puerto Rico
Serbia
Myanmar
Sweden
Senegal
Taiwan
Rwanda
Tunisia
Zambia
Slovenia
Sierra Leone
San Marino
Thailand
Uruguay
Portugal
Uzbekistan
Russian Federation
Turkey
El Salvador
Ukraine
Uganda
Venezuela
Dominican Republic
Namibia
Iceland
Liechtenstein
Azerbaijan
Nigeria
Bahamas
Iraq
United Arab Emirates
Morocco
Jamaica
Honduras
Bolivia
Isle of Man
Norway
Luxembourg
Mexico
Pakistan
Albania
Panama
Lithuania
Romania
Grenada
Bangladesh
Argentina
Jordan
Nicaragua
Mali
Lebanon
Mauritius
Philippines
Israel
Jersey
Malaysia
Malta
Kazakhstan
Kenya
Italy
Cayman Islands
Cambodia
Cameroon
Cyprus
Oman
Latvia
Austria
Switzerland
Guatemala
Colombia
Marshall Islands
VC (Venture Capital) Funds in Iceland by industry
Manufacturing
Financial Services
Climate
Marketplace
Education
Payments
Food and Beverage
Video Games
Medical
Medical Device
Big Data
Internet
Android
Mobile
Enterprise Software
Platforms
FinTech
Enterprise
Biotechnology
Health Care
EdTech
Artificial intelligence
Community
Gaming
Hardware
Sports
Media (entertainment)
Software
Biotech
Energy
SaaS
Transportation